Ribociclib: observed

46 studies: patients on it are followed, or it is given outside a trial. Page 1 of 1. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.

Clinical and Therapeutic Outcomes by Molecular Subtype in Breast CancerRecruitingNCT07856225 Report a problem
Real-world Studies of CDK4/6 InhibitorsRecruitingNCT07407439 Report a problem
Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.RecruitingNCT07243002 Report a problem
Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast CancerRecruitingNCT07180056 Report a problem
Concomitant Radiotherapy and New Drugs in Metastatic Breast CancerRecruitingNCT07021911 Report a problem
Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in RussiaRecruitingNCT06930859 Report a problem
Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world PracticeRecruitingNCT06905301 Report a problem
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of RecurrenceRecruitingNCT06830720 Report a problem
Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 StudyRecruitingNCT06805812 Report a problem
RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi ArabiaRecruitingNCT06797531 Report a problem
Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast CancerRecruitingNCT06587789 Report a problem
DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer PatientsRecruitingNCT06388122 Report a problem
A Study of the Gut Microbiome in Hormone Receptor-positive HER2-negative Breast Cancer Treated With CDK4/6 InhibitorsRecruitingNCT06171360 Report a problem
Managed Access Programs for LEE011, RibociclibAvailableNCT05038631 Report a problem
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast CancerRecruitingNCT04660435 Report a problem
A Real-World Study of Treatment Patterns, Tolerability and Effectiveness of CDK4/6 Inhibition in HR+, HER2-negative Metastatic Breast Cancer PatientsCompletedNCT07760714 Report a problem
A Real-World Study of Clinical Adoption, Treatment Patterns and Tolerability of Adjuvant Ribociclib in HR+/HER2- Early Breast Cancer PatientsActive, not recruitingNCT07710716 Report a problem
A Real-World Study of Early Breast Cancer Patients Eligible for Treatment With CDK4/6 InhibitorsCompletedNCT07647042 Report a problem
A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 InhibitorsCompletedNCT07512063 Report a problem
Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)WithdrawnNCT07475923 Report a problem
A Real-world Study of Indian Patients With Advanced Breast Cancer Treated With RibociclibCompletedNCT07363434 Report a problem
Emulation of the MONALEESA-2 Trial Using Specialty Oncology Electronic Health Records DatabasesCompletedNCT07274709 Report a problem
Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in PortugalCompletedNCT07223476 Report a problem
A Study of Real-world Outcomes Among Patients Treated With RibociclibCompletedNCT07148505 Report a problem
A Study of Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast CancerCompletedNCT07086196 Report a problem
An Indirect Treatment Comparison of the Effectiveness of Ribociclib Combined With Non-steroidal Aromatase Inhibitors vs. Tamoxifen for the Adjuvant Treatment of Premenopausal Women With Hormon Receptor-positive, HER2-negative Early Breast CancerCompletedNCT07072013 Report a problem
Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) StudyActive, not recruitingNCT07008508 Report a problem
A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or AlpelisibCompletedNCT06705504 Report a problem
A Prospective Non-interventional Study to Evaluate Clinical Outcomes of Ribociclib Combined With Endocrine Therapy in Elderly Patients With HR+HER2 - Advanced Breast Cancer in Routine Clinical Practice in Russian FederationActive, not recruitingNCT06625333 Report a problem
Observational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breast Cancer Treated With ChemotherapyCompletedNCT06619704 Report a problem
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast CancerActive, not recruitingNCT06495164 Report a problem
Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL StudyCompletedNCT06463626 Report a problem
Characteristics and Predictors of Liver Injury in Cyclin-dependent Kinase Inhibitors 4/6 (CDK4/6)-Treated Patients With Advanced Breast CancerCompletedNCT06367335 Report a problem
A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line TreatmentCompletedNCT06311383 Report a problem
A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the RussiaActive, not recruitingNCT06148506 Report a problem
Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.TerminatedNCT06126003 Report a problem
A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast CancerCompletedNCT06075758 Report a problem
Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in FranceActive, not recruitingNCT05697146 Report a problem
A Deep Learning Method to Evaluate QT on RibociclibCompletedNCT05623397 Report a problem
Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast CancerCompletedNCT05569187 Report a problem
Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 InhibitorsCompletedNCT05153135 Report a problem
A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 InhibitorsCompletedNCT05141240 Report a problem
Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?Status unknownNCT05051956 Report a problem
A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in RussiaCompletedNCT04943497 Report a problem
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.Status unknownNCT04852081 Report a problem
A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With BreastcancerCompletedNCT03956654 Report a problem

← Ribociclib